Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.56 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257847 | 0.82 | MLYCD (0.69) | MLYCDMEN1KMT2AROCK2ROCK1 | |
| SCHEMBL12133560 | 0.81 | MLYCD (0.72) | MLYCDMEN1KMT2ACDK4CCND1 | |
| SCHEMBL13306259 | 0.80 | TPMT (0.52) | MEN1KMT2ATPMT | |
| SCHEMBL27891608 | 0.79 | MLYCD (0.65) | MLYCDLTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL3469796 | 0.78 | TPMT (0.48) | KDM4ETPMT | |
| SCHEMBL8302947 | 0.76 | LPAR1 (0.57) | MLYCDMEN1KMT2ALPAR1POLB | |
| SCHEMBL15676740 | 0.75 | KMT2A (0.59) | MLYCDLTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL1696479 | 0.74 | KMT2A (0.57) | MLYCDLTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL30498665 | 0.74 | KMT2A (0.52) | MLYCDLTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL8242118 | 0.74 | MEN1 (0.57) | MLYCDLTB4RLTB4R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | claimed |
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-7294642-B2 | 1,3-Diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | MLYCD 3237/4885LTB4R 1725/4885LTB4R2 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.